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H I G H L I G H T S    
• Elevated pre-procedure heart rate was an independent predictor of all-cause mortality at 2 years following percutaneous coronary intervention (PCI).  • Elevated pre-procedure heart rate did not impact the bleeding events at 2 years following PCI.  • Ticagrelor monotherapy versus standard dual antiplatelet therapy did not improve the bad ischemic prognosis of high pre-procedure heart rate.  
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A B S T R A C T   
Background and aims: The prognostic impact of pre-procedure heart rate (PHR) following percutaneous coronary 
intervention (PCI) has not yet been fully investigated. This post-hoc analysis sought to assess the impact of PHR 
on medium-term outcomes among patients having PCI, who were enrolled in the “all-comers” GLOBAL LEADERS 
trial. 
Methods and results: The primary endpoint (composite of all-cause death or new Q-wave myocardial infarction 
[MI]) and key secondary safety endpoint (bleeding according to Bleeding Academic Research Consortium 
[BARC] type 3 or 5) were assessed at 2 years. PHR was available in 15,855 patients, and when evaluated as a 
continuous variable (5 bpm increase) and following adjustment using multivariate Cox regression, it 
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significantly correlated with the primary endpoint (hazard ratio [HR] 1.06, 95% confidence interval [CI] 
1.03–1.09, p  <  0.001). Using dichotomous cut-off criteria, a PHR > 67 bpm was associated with increased all- 
cause mortality (HR 1.38, 95%CI 1.13–1.69, p = 0.002) and more frequent new Q-wave MI (HR 1.41, 95%CI 
1.02–1.93, p = 0.037). No significant association was found between PHR and BARC 3 or 5 bleeding (HR 1.04, 
95% CI 0.99–1.09, p = 0.099). There was no interaction with the primary (p-inter = 0.236) or secondary 
endpoint (p-inter = 0.154) when high and low PHR was analyzed according to different antiplatelet strategies. 
Conclusions: Elevated PHR was an independent predictor of all-cause mortality at 2 years following PCI in the 
“all-comer” GLOBAL LEADERS trial. The prognostic value of increased PHR on outcomes was not affected by the 
different antiplatelet strategies in this trial.   
1. Introduction 
Previous studies have demonstrated that resting heart rate is a risk 
factor for mortality in patients with coronary artery disease (CAD) [1–3], 
heart failure [4,5] and even in the general population [6,7]. Given the 
association between heart rate and subsequent higher rates of adverse 
outcomes, the need to identify the relationship between heart rate and 
CAD patients in the modern era of primary percutaneous coronary inter-
vention (PCI), is of interest. The few studies that have examined the as-
sociation of heart rate and clinical outcomes following PCI have mainly 
focused on patients with acute coronary syndrome (ACS) [8,9]. The 
prognostic impact of heart rate on outcomes in a wide spectrum of CAD 
patients who underwent PCI has not yet been fully investigated. In addi-
tion, whilst O'Brien et al. identified that pre-procedure heart rate (PHR) is 
an independent predictor of adverse outcomes in a registry of patients 
undergoing PCI, this was only for short-term (30-day) outcomes [10]. 
Consequently, whether an elevated PHR is related to an increased risk of 
adverse outcomes after PCI in a wide spectrum of CAD patients (including 
patients with stable CAD or ACS) during medium-term follow-up remains 
unknown. Therefore, in this study, we aimed to evaluate the impact of 
PHR on 2-year clinical outcomes following PCI in the prospective, con-
temporary “all-comer” GLOBAL LEADERS trial. 
2. Patients and methods 
The design of the GLOBAL LEADERS trial has been reported pre-
viously elsewhere [11]. Briefly, patients were randomized before PCI to 
the experimental strategy of 23-month ticagrelor monotherapy (after 1- 
month of ticagrelor and aspirin), versus the reference strategy of 12- 
month dual antiplatelet treatment (aspirin and either ticagrelor for ACS 
or clopidogrel for stable CAD) followed by 12 months of aspirin 
monotherapy. The trial was conducted at 130 hospitals in 18 countries 
with a total of 15,991 patients in an “all-comer” design [12]. Of those, 
15,855 participants were included in the present analysis (23 withdrew 
consent and requested the deletion of their data from the database; 85 
did not undergo PCI and were treated with medical therapy alone or 
urgent coronary artery bypass grafting [CABG]; 28 were excluded due 
to missing data on heart rate; Supplementary Fig. S1). 
The primary endpoint was composite endpoint of all-cause death or 
new Q-wave myocardial infarction (MI) at 2 years. Deaths from any 
cause were ascertained without adjudication. Q-wave MI was defined in 
compliance with the Minnesota classification (new major Q wave ab-
normalities) or by the appearance of a new left bundle branch block in 
conjunction with symptoms, abnormal cardiac biomarkers, or loss of 
myocardial viability. Electrocardiogram (ECG) was examined at dis-
charge, 3-month and 2-year follow up and when ischemic events were 
suspected or if repeat revascularization was performed. All ECGs were 
adjudicated at the core laboratory with the Minnesota classification 
(Cardialysis, Rotterdam, Netherlands) by analysts and physicians who 
were blinded to the treatment allocation [13,14]. The key secondary 
safety endpoint was site-reported bleeding assessed according to the 
BARC criteria (type 3 or 5) [15]. Time to first event was used for the 
analysis. PHR was obtained in the 24 h prior to PCI. All patients data 
were prospectively collected in the trial. The trial was approved by the 
institutional review board or ethics committee at each center and fol-
lowed the ethical principles of the Declaration of Helsinki. All the pa-
tients signed written informed consent prior to participation in the trial. 
Continuous data are presented as mean  ±  standard deviation or 
medians and 25th and 75th percentiles as appropriate. Categorical data 
are expressed as frequencies and percentages. Continuous variables were 
compared using the Mann-Whitney U test. Categorical variables were 
compared with the χ 2 test. The relationship between PHR, as either a 
continuous or categorical variable, and adverse outcomes was evaluated 
by multivariable Cox proportional hazards regression models. Baseline 
variables that were considered clinically relevant or that showed a uni-
variate relationship with outcomes were entered into the multivariate Cox 
proportional hazards regression model. Variables for inclusion were 
carefully chosen, given the number of events available, to ensure parsi-
mony of the final model. Three models were fitted for the current analysis: 
model 1 was adjusted for age and gender; model 2 for conventional risk 
factors including hypertension, systolic and diastolic blood pressure, dia-
betes, hypercholesterolemia, impaired renal function, body-mass index 
(BMI), chronic obstructive pulmonary diseases (COPD), peripheral vas-
cular disease (PVD), left ventricular ejection fraction (LVEF); and model 3 
was corrected for age, gender, conventional risk factors and previous 
medical history including previous stroke, MI, CABG and major bleeding, 
which were all associated with the primary endpoint with a p value  <  0.1 
in the univariate analysis. Elevated PHR was analyzed as a continuous 
variable in primary analyses, and then as a categorical variable using the 
cut-off value of 67 bpm, which was derived from the maximally selected 
rank statistics analysis (Supplementary Fig. S2). We performed an adjusted 
cubic spline model to show the relationship between PHR, as a continuous 
covariate, and adverse outcomes using 60 bpm as the reference. Events 
rates were plotted in Kaplan-Meier curves for all-cause death, and BARC 3 
or 5 bleeding according to heart rate tertiles (< 64 bpm, 64–73 bpm, > 73 
bpm), and the log-rank test was used for comparisons among groups. In 
addition, interaction testing on outcomes between PHR and antiplatelet 
strategy was assessed in the Cox regression model using PHR as a di-
chotomous variable. All tests were 2-sided, and a p value  <  0.05 was 
considered statistically significant. All statistical analyses were performed 
with SPSS software (version 25.0, SPSS Inc., Chicago, IL, USA). 
3. Results 
A total of 15,855 patients with available PHR were analyzed. The 
median age was 65 [57–72] years, and 76.7% were men. The dis-
tribution of PHR in the overall study population is shown in  
Supplementary Fig. S3; the median PHR was 69 [60–76] bpm. Baseline 
characteristics according to the cut-off PHR of 67 bpm are reported in  
Table 1. Compared to patients with a PHR≤67 bpm, patients with 
PHR > 67 bpm were more likely to be female, younger, current smo-
kers, with higher BMI, and higher rates of diabetes, hypertension, 
COPD, ACS, previous stroke, MI, PCI or CABG and a lower LVEF. They 
were less likely to have hypercholesterolemia. No significant differ-
ences were found between the two groups (high PHR vs low PHR) in 
rates of PVD, impaired renal function and previous major bleeding. 
The clinical outcomes are presented in Table 2. At 2-year follow-up, 
the primary endpoint (consisting of all-cause death or new Q-wave MI) 
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occurred in 648 (4.09%) patients in the overall population, 244 
(3.31%) patients in the group with PHR≤67 bpm, and 404 (4.76%) 
patients in the group with PHR > 67 bpm (adjusted HR for PHR > 67 
bpm vs PHR≤67 bpm: 1.38, 95% CI [1.17–1.64]). The secondary 
endpoint (BARC 3 or 5 bleeding) was observed in 331 (2.09%) patients 
in the overall population, 147 (2.00%) patients in the group with 
PHR≤67 bpm and 184 (2.17%) patients in the group with PHR > 67 
bpm (adjusted HR for PHR > 67 bpm vs PHR≤67 bpm: 1.06, 95% CI 
[0.84–1.34]). 
Kaplan-Meier curves for all-cause mortality and BARC 3 or 5 
bleeding up to 2 years according to heart rate tertiles are shown in  
Fig. 1. Patients in the group with a PHR > 73 bpm had significant 
higher rates for all-cause mortality (3.70% vs 2.47%, p = 0.0005) 
compared with the lowest tertile with a PHR < 64 bpm. On the con-
trary, bleeding event rates among groups were comparable. A 
multivariable analysis was conducted to evaluate the impact of PHR on 
clinical outcomes. Three models were fitted for analysis as described 
earlier. The association between clinical outcomes and increased PHR 
using the 3 multivariable Cox proportional hazards models is shown in  
Table 3. In model 3, when using PHR as a continuous variable, each 5 
bpm increase in PHR resulted in a significant 6% increased risk of the 
primary endpoint, which was mainly driven by the increased risk of the 
all-cause mortality (HR 1.07, 95% CI 1.03–1.11, p  <  0.001). Increased 
PHR represented a higher cardiovascular death (HR 1.10, 95% CI 
1.04–1.15, p  <  0.001). As a continuous covariate, increases in PHR did 
not have any significant relationship with new Q-wave MI or the sec-
ondary endpoints. The adjusted cubic spline model was performed to 
investigate the relationship between continuous PHR and outcomes.  
Fig. 2 shows that increases in PHR were associated with a higher risk of 
all-cause mortality in a J shaped distribution. 
Table 1 
Baseline characteristics of patients.       
≤67 bpm  
(N = 7363)  
> 67 bpm  
(N = 8492) 
p-value  
Age, years 65 [58–73] 64 [57–72]  < 0.001 
BMI 27.4 [24.9–30.2] 27.8 [25.2–31.1]  < 0.001 
Male 79.2 (5829/7363) 74.6 (6336/8492)  < 0.001 
Female 20.8 (1534/7363) 25.4 (2156/8492)  < 0.001 
DM 21.5 (1585/7359) 28.6 (2427/8485)  < 0.001 
Insulin-dependent DM 6.2 (457/7346) 9.0 (759/8462)  < 0.001 
Hypertension 72.4 (5313/7335) 74.7 (6327/8466) 0.001 
Systolic blood pressure 135 [120–150] 137 [122–150]  < 0.001 
Diastolic blood pressure 75 [68–81] 80 [70–87]  < 0.001 
Hypercholesterolaemia 70.9 (5096/7189) 68.6 (5599/8164) 0.002 
Current smoker 24.3 (1790/7363) 27.8 (2358/8492)  < 0.001 
PVD 6.4 (464/7288) 6.3 (530/8422) 0.850 
COPD 4.5 (328/7331) 5.7 (484/8453)  < 0.001 
Previous major bleeding 0.6 (45/7355) 0.6 (53/8479) 0.916 
Impaired renal functiona 13.2 (965/7319) 14.1 (1192/8452) 0.094 
Previous stroke 2.1 (155/7352) 3.1 (263/8480)  < 0.001 
Previous MI 25.1 (1841/7342) 21.8 (1845/8469)  < 0.001 
Previous PCI 36.0 (2646/7357) 29.9 (2538/8484)  < 0.001 
Previous CABG 6.9 (507/7358) 5.1 (430/8484)  < 0.001 
Stable CAD 56.7 (4178/7363) 49.8 (4228/8492)  < 0.001 
ACS 43.3 (3185/7363) 50.2 (4264/8492)  < 0.001 
Unstable angina 12.9 (950/7363) 12.5 (1058/8492)  
Non-STEMI 20.5 (1508/7363) 21.8 (1849/8492)  
STEMI 9.9 (727/7363) 16.0 (1357/8492)  
LVEF 55 [50–62] 55 [50–60]  < 0.001 
Data are % (n/N), unless otherwise specified. 
BMI: body-mass index, DM: diabetes mellitus, PVD: peripheral vascular disease, COPD: chronic obstructive pulmonary disease, myocardial infarction, 
PCI: percutaneous coronary intervention, CABG: coronary artery bypass grafting, CAD: coronary artery disease, ACS: acute coronary syndrome, 
STEMI: ST elevation myocardial infarction, LVEF: left ventricular ejection fraction. 
a Defined as an estimated glomerular filtration rate of creatinine clearance of < 60 mL/min per 1.73 m2 based on the Modification of Diet in Renal 
Disease formula.  
Table 2 
Two-year outcomes in the overall population and 2 groups divided by 67 bpm.        
Outcomes ≤67 bpm 
% (n/N)  




Unadjusted HR  
> 67 bpm vs ≤ 67 bpm 
Adjusted HR  
> 67 bpm vs ≤ 67 bpm  
All-cause mortality or new Q-wave MI 3.31 (244/7363) 4.76 (404/8492) 4.09 (648/15855) 1.45 (1.24–1.70) 1.38 (1.17–1.64) 
All-cause mortality 2.38 (175/7363) 3.50 (297/8492) 2.98 (472/15855) 1.48 (1.23–1.79) 1.38 (1.13–1.69) 
Cardiovascular death 0.96% (71/7363) 1.84% (156/8492) 1.43% (227/15855) 1.92 (1.45–2.54) 1.64 (1.21–2.21) 
New Q-wave MI 0.98 (72/7363) 1.34 (114/8492) 1.17 (186/15855) 1.39 (1.03–1.86) 1.41 (1.02–1.93) 
BARC 3 or 5 bleeding 2.00 (147/7363) 2.17 (184/8492) 2.09 (331/15855) 1.10 (0.88–1.36) 1.06 (0.84–1.34) 
BARC 5 bleeding 0.27 (20/7363) 0.31 (26/8492) 0.29 (46/15855) 1.14 (0.63–2.03) 1.03 (0.55–1.93) 
BARC 3 bleeding 1.83 (135/7363) 2.04 (173/8492) 1.94 (308/15855) 1.12 (0.90–1.41) 1.09 (0.85–1.38) 
Adjusted for age, gender, hypertension, systolic and diastolic blood pressure, diabetes, hypercholesterolemia, impaired renal function, BMI, COPD, PVD, LVEF and 
previous stroke, MI, CABG or major bleeding. 
MI: myocardial infarction.  
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When PHR was analyzed as a dichotomous variable, the hazard 
ratios for patients with PHR > 67 bpm vs. PHR≤67 group were 1.38 
(95% CI 1.17–1.64, p  <  0.001) for the primary endpoint, 1.38 (95% CI 
1.13–1.69, p = 0.002) for all-cause mortality, 1.64 (95% CI 1.21–2.21, 
p = 0.001) for cardiovascular death and 1.41 (95% CI 1.02–1.93, 
p = 0.037) for new Q-wave MI. On the contrary, no significant dif-
ference was observed in BARC 3 or 5 bleeding events rates between the 
two groups. The interaction term between antiplatelet strategy and PHR 
was negative for the primary and secondary endpoint (p-inter = 0.236, 
p-inter = 0.154, respectively, Supplementary Table S1). Furthermore, 
the clinical presentation of ACS or stable CAD did not interact with the 
prognostic role of PHR on the primary (p-inter = 0.528) or secondary 
endpoint (p-inter = 0.164). Similarly, the presence or absence of dia-
betes or impaired renal function did not change the impact of PHR on 
the primary (p-inter = 0.129 and p-inter = 0.942 for diabetes and 
impaired renal function, respectively) or secondary endpoint (p- 
inter = 0.823 and p-inter = 0.773 for diabetes and impaired renal 
function, respectively) either. 
4. Discussion 
In a large size contemporary “all-comer” population with both 
stable CAD and ACS following PCI in GLOBAL LEADERS trial, we found: 
1) elevated PHR is an independent predictor of all-cause mortality and 
cardiovascular death; 2) each increase of 5 bpm in PHR is associated 
with a significant 7% increased risk of for all-cause mortality; 3) 
PHR > 67 bpm was an independent predictor of all-cause mortality, 
cardiovascular death and new Q-wave MI; 4) no significant relationship 
exists between PHR and bleeding events; and 5) the prognostic value of 
increased PHR on outcomes was not affected by the two antiplatelet 
strategies. 
Previous studies have demonstrated that heart rate was an in-
dependent predictor of adverse outcomes in various populations, in-
cluding patients with hypertension, CAD, left ventricular dysfunction 
and even in general populations [1–7,16,17]. However, there are very 
few prospective studies that have evaluated the relationship between 
heart rate and adverse outcomes in the full spectrum of CAD patients 
Fig. 1. Kaplan–Meier time-to-event plots for clinical outcome at 2-year follow-up for PHR in tertiles. 
(A) All-cause mortality, (B) BARC 3 or 5 bleeding. PHR: pre-procedure heart rate. 
Table 3 
Clinical outcomes and heart rate as continuous and binary variable.          
Outcomes 
Model 1 Model 2 Model 3 
Adjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value  
All-cause mortality or new Q-wave MI 
PHR > 67 bpm vs PHR≤67 bpm 1.52 (1.29–1.78)  < 0.001 1.33 (1.13–1.58) 0.001 1.38 (1.17–1.64)  < 0.001 
PHR higher by 5 bpm 1.08 (1.05–1.11)  < 0.001 1.05 (1.02–1.08) 0.003 1.06 (1.03–1.09)  < 0.001 
All-cause mortality 
PHR > 67 bpm vs PHR≤67 bpm 1.56 (1.30–1.89)  < 0.001 1.34 (1.10–1.63) 0.004 1.38 (1.13–1.69) 0.002 
PHR higher by 5 bpm 1.10 (1.06–1.14)  < 0.001 1.06 (1.02–1.10) 0.002 1.07 (1.03–1.11)  < 0.001 
Cardiovascular death 
PHR > 67 bpm vs PHR≤67 bpm 2.00 (1.51–2.64)  < 0.001 1.64 (1.21–2.21) 0.001 1.64 (1.21–2.21) 0.001 
PHR higher by 5 bpm 1.14 (1.09–1.19)  < 0.001 1.09 (1.04–1.15)  < 0.001 1.10 (1.04–1.15)  < 0.001 
New Q-wave MI 
PHR > 67 bpm vs PHR≤67 bpm 1.42 (1.05–1.90) 0.021 1.34 (0.98–1.83) 0.068 1.41 (1.02–1.93) 0.037 
PHR higher by 5 bpm 1.03 (0.98–1.09) 0.247 1.03 (0.97–1.09) 0.387 1.04 (0.98–1.10) 0.252 
BARC 3 or 5 bleeding 
PHR > 67 bpm vs PHR≤67 bpm 1.13 (0.91–1.40) 0.277 1.04 (0.83–1.31) 0.741 1.06 (0.84–1.34) 0.611 
PHR higher by 5 bpm 1.05 (1.01–1.10) 0.018 1.03 (0.99–1.08) 0.156 1.04 (0.99–1.09) 0.099 
BARC 5 bleeding 
PHR > 67 bpm vs PHR≤67 bpm 1.16 (0.64–2.08) 0.627 0.97 (0.52–1.80) 0.917 1.03 (0.55–1.93) 0.924 
PHR higher by 5 bpm 1.05 (0.94–1.18) 0.349 1.01 (0.89–1.14) 0.925 1.02 (0.90–1.16) 0.717 
BARC 3 bleeding 
PHR > 67 bpm vs PHR≤67 bpm 1.15 (0.92–1.44) 0.218 1.06 (0.84–1.35) 0.623 1.09 (0.85–1.38) 0.505 
PHR higher by 5 bpm 1.05 (1.01–1.10) 0.018 1.03 (0.99–1.08) 0.148 1.04 (0.99–1.09) 0.094 
Model 1 was adjusted for age and gender. 
Model 2 was adjusted for hypertension, systolic and diastolic blood pressure, diabetes, hypercholesterolemia, impaired renal function, BMI, COPD, PVD and LVEF. 
Model 3 was adjusted for age, gender, hypertension, systolic and diastolic blood pressure, diabetes, hypercholesterolemia, impaired renal function, BMI, COPD, PVD, 
LVEF and previous stroke, MI, CABG or major bleeding. 
MI: myocardial infarction, PHR: pre-procedure heart rate.  
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undergoing PCI [18]. Pre-procedure heart rate has recently been shown 
by O'Brien et al. [10] to be an independent predictor of adverse 30-day 
cardiovascular outcomes in 3720 patients after PCI. However, whilst 
higher PHR was not an independent predictor of 30-day mortality, it 
was a predictor of 30-day MACE (death, MI and target vessel re-
vascularization [TVR]) when PHR was analyzed in quintiles, suggesting 
that a sample size of 3720 patients may not be significantly powered for 
a single event such as all-cause death. Therefore, in the present large 
size study, we also examined the relationship between PHR and out-
come at 30-days, as well as in a prespecified 30 days landmark analysis 
up to 2-years. No association with 30-day primary or secondary end-
points was seen when using PHR as a dichotomous variable even after 
adjustment. However, as a continuous variable, each 5 bpm increase in 
PHR was associated with a significant 14% increased risk of all-cause 
mortality at 30 days (Supplementary Table S2 and Table S3). This 
difference may be due to the relatively small number of deaths at 30- 
day follow-up (only 0.26% [19/7363] deaths in the PHR≤67 bpm 
group and 0.57% [48/8492] deaths in the PHR > 67 bpm group), 
suggesting that analysis of PHR as a continuous value would be more 
powerful than by a categorical approach. Further studies, especially in a 
high risk population, are still needed to investigate the prognostic role 
of heart rate on short term outcomes. 
More recently, a single-center retrospective cohort study indicated 
that PHR is an independent predictor of adverse outcomes at 10-year 
follow-up in 6049 CAD patients who underwent PCI. High PHR was 
associated with an increased risk of all-cause mortality, but had no 
relationship with bleeding events [19]. Our analysis confirmed these 
findings in a multicenter, much larger size CAD population. To our 
knowledge, this is the first time that the relationship between heart rate 
and adverse outcomes has been investigated in a larger, multicenter, 
prospective, contemporary, all-comers PCI trial. Supplementary Table 
S4 shows the characteristics and results of the present study and pre-
vious ones [10,18,19]. 
Heart rate is an easily measured and readily available clinical sign. 
However, to date there is no defined threshold heart rate for 
consideration of preventive treatment in contemporary CAD patients 
undergoing PCI. In the current study, our observations suggest a 
threshold of 67 bpm, as a poor prognosis was observed when PHR was 
higher than 67 bpm. Most previous studies chose their cut-off values 
arbitrarily (or according to previous studies); however, we used maxi-
mally selected rank statistics analysis to establish a cut-off which would 
be the most specific and sensitive in assessing the relationship between 
heart rate and outcomes, although the C statistic and Youden's index 
were very low (C statistic = 0.56, Youden's index: 0.097). In contrast to 
other methodological approaches, maximally selected rank statistics to 
find the optimal cut-off value is statistically suitable for survival ana-
lysis [20]. The threshold heart rate in our analysis is slightly lower than 
in previous studies [3,8,9,19], which may be a consequence of the 
heterogenous study cohorts enrolled. Further studies are needed to 
define a critical threshold beyond which therapeutic prospective in-
tervention (e.g. pharmacological therapy) might be recommended to 
reduce the frequency of adverse outcomes. 
Since the higher heart rate predicts worse clinical outcomes, heart 
rate-lowering medications, particularly beta-blockers, have been asso-
ciated with the prevention of angina and reduction of myocardial 
ischemia [3]. Accordingly, the predictive impact of heart rate on ad-
verse outcomes may be influenced by the use of beta-blocker. However, 
several studies demonstrated the impact of heart rate on outcomes were 
not affected by beta-blocker use [1,9,18,19], suggesting heart rate 
predicts the adverse outcomes independently. In our trial, beta-blocker 
use was not recorded at baseline before PCI, however, after adjustment 
for the use of beta-blocker, ACE inhibitor, angiotensin receptor blocker, 
and statin at discharge, heart rate still was an independent risk factor to 
the primary and secondary endpoint. 
The mechanisms explaining the deleterious effects of increased 
heart rate is likely to be multifactorial. An imbalance between oxygen 
demand and supply could contribute to myocardial ischemia. An ele-
vated heart rate leads to an increase myocardial oxygen consumption 
and also reduces the diastolic time, resulting in reduced coronary blood 
flow, and therefore to lower oxygen supply [21]. Increased heart rate 
impairs endothelial function in animal models and may contribute to 
reduced shear stress and vascular compliance [22]. Heart rate was also 
associated with calcification of left-sided heart valves, which has been 
associated with increased risk of cardiovascular disease mortality [23]. 
Increased inflammation has been thought to play an important role in 
the development, progression, and disruption of atherosclerotic plaques 
[24]. Whelton et al. [25] reported that an increased resting heart rate 
was associated with a higher level of inflammation, and the effects of 
this on cardiovascular mortality appear to be strongly amplified by a 
faster resting heart rate [26]. Plaque disruption is the central patho-
physiological mechanism underlying ACS and the progression of cor-
onary atherosclerosis. Heidland et al. reported positive associations 
between plaque disruption and a mean heart rate > 80 bpm and a 
negative association with the use of beta -blockers. These findings may 
help identify patients who are at a high risk of plaque disruption and 
who may benefit from medical interventions aimed at reducing heart 
rate [27]. 
Our analysis has several strengths, which include a large sample 
size, a wide spectrum of CAD clinical presentation and a relatively long 
follow-up. There are also some limitations. First, the present study is a 
post hoc analysis, and should be considered hypothesis-generating. 
Second, in the GLOBAL LEADERS trial there was no detailed informa-
tion on heart rhythm, therefore, we could not exclude atrial fibrillation 
(AF) as a cause of high heart rate, however, patients who needed anti- 
coagulation were excluded. More importantly, prior studies reported 
that the prognostic impact of high heart rate on outcomes was not 
specifically documented in AF [28,29]. Finally, given the large popu-
lation and relative large event number, we adjusted the multiple Cox 
proportional-hazard regression models for all available and clinical 
relevant confounders, even though, not all confounders may have been 
identified. 
Fig. 2. Association of PHR and all-cause mortality in an adjusted cubic spline 
model. 
The adjusted cubic spline model shows the relationship between PHR and all- 
cause mortality, when taking 60 bpm as the reference. Adjusted for age, gender, 
hypertension, systolic and diastolic blood pressure, diabetes, hypercholester-
olemia, impaired renal function, BMI, COPD, PVD, LVEF and previous stroke, 
MI, CABG or major bleeding. 
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In conclusion, elevated PHR was an independent predictor of all- 
cause mortality and cardiovascular death at 2 years following PCI in a 
contemporary “all-comer” trial. The prognostic value of increased PHR 
on outcomes was not affected by the randomized allocation to the ex-
perimental or reference antiplatelet therapy. Further studies are war-
ranted to define a critical threshold heart rate for targeted intervention 
in contemporary CAD patients following PCI. 
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